Peplinski and Albiani Smith first reported the incidence of DUES in bimatoprost. 5 The incidence of DUES due to prostaglandins was 25-60%. [6][7][8][9] It was found to be considerably higher with bimatoprost than with other PGAs.
P rostaglandin analogs (PGAs) have become first-line drugs for controlling intraocular pressure (IOP) in glaucoma and ocular hypertension (OHT) patients. In addition to their effectiveness in IOP reduction, the once daily dose improves patient compliance. The mechanism of action in IOP reduction is increasing uveoscleral outflow.
1 Prostaglandin analogs are a group of drugs: bimatoprost, latanoprost, travoprost, and the newer tafluprost. Their common side effects are conjunctival hyperemia, eyelash change (hypertrichosis, darkening of the eyelashes), iris darkening, eyelid skin hyperpigmentation, and ocular surface problems.
2-3 Their less common side effects are cystoid macular edema, iris cysts, and systemic side effects in pregnancy. [2] [3] Another local side effect that becomes of concern is prostaglandin-associated periorbitopathy (PAP). Prostaglandin-associated periorbitopathy is a group of clinical findings that consists of an absence of dermatochalasis, a deep crease in the upper eyelid, ptosis of the upper eyelid, decreased prominence of the inferior orbital fat pads, enophthalmos, orbital fat atrophy, flattening of the lower eyelid bags, inferior scleral show, tight orbits, and deepening of the upper eyelid sulcus (DUES). Prostaglandin-associated periorbitopathy affects patient care in many ways: difficulty in IOP measurement, difficulty during surgery, and cosmetic concerns. This was a cross-sectional, analytic, observer-masked study. The study protocol was approved by the Institutional review Board of the Faculty of Medicine, chulalongkorn University, Bangkok, Thailand (chairperson: Professor Emeritus T. Sueblinvong, MD) on March 20, 2014 (IrB no. 008/57) and registered with the Thai Clinical Trial Registry (TcTr20141011001). This study was conducted in accordance with the Declaration of Helsinki.
One hundred thirty-four consecutive eligible subjects from the general ophthalmology and glaucoma outpatient clinic of the Department of Ophthalmology, King chulalongkorn Memorial Hospital (KcMH) were included from May 2014 through February 2015. Inclusion criteria were 1) patients diagnosed with glaucoma or OHT who had been using PGAs with or without 0.5% timolol to lower IOP for at least 3 months and 2) aged 18 or older. Patients who used antiglaucoma drugs other than PGAs and 0.5% timolol; had a history of ocular surgery except cataract, filtering surgery, or glaucoma laser treatment; and patients who had generalized lipodystrophy were excluded. Informed consent to participate in this study was obtained from all patients.
To determine PAP, an 8.0 megapixel canon IXUS 860 IS digital camera was used to take a photograph of the patient's demographic data eye at a distance of 30 cm without flash in ambient lighting. A set of photographs taken from an individual comprised the eye along with the eyebrows and the area below the lower eyelids in 3 positions: facing forward, worm-eye view, and aside. All photos were taken by one of the authors (c.P.). Photography was utilized for evaluation rather than performing assessments in the actual patients in an attempt to minimize evaluator bias. Patient data were then concurrently collected.
Evaluators were instructed regarding the characteristics of PAP, including DUES, absence of dermatochalasis, a deep crease in the upper eyelid, ptosis of the upper eyelid (defined as position of the upper eyelid more than 2 mm inferior to the upper limbus), decreased prominence of the inferior orbital fat pads, inferior scleral show, enophthalmos, and orbital fat atrophy. 5, 10, 11 All photographs were in different sequences before being presented to 2 glaucoma specialists (V.T. and A.M.) for evaluation. Each specialist independently evaluated the photographs. To determine intra-and interobserver reliability, the same process was repeatedly performed. Patients were diagnosed with PAP if they had 1 major clinical appearance (DUES) with at least 3 additional clinical appearances.
The factors included in this study were sex, age, body mass index (BMI), types of PGAs, types of glaucoma, duration of PGA use, and additional 0.5% timolol. Subjects were divided into 2 age groups: age 60 or younger and older than 60 years. Body mass index [weight (in kilograms) divided by height (in square meters)] was estimated from self-reported current height and weight. According to the World Health Organization (WHO), BMI classification for Asian people consists of 3 groups, namely, less than 18.5 kg/m 2 (underweight), 18.5 to 22.9 kg/m 2 (normal range), and more than 23 kg/m 2 (overweight). 12 Types of glaucoma were categorized as open angle, angle closure, secondary glaucoma, and OHT. Types of PGAs included in the study were 0.005% latanoprost, 0.03% bimatoprost, and 0.004% travoprost. Duration of use was divided into 3-6 months and more than 6 months. As KcMH is a tertiary care and referral center, many subjects took more than a single antiglaucoma drug and 0.5% timolol was most frequently used with PGAs. Therefore, in this study, we assessed the effect of 0.5% timolol on PAP in both concurrent 0.5% timolol use and in fixed combination PGA/timolol.
The data were analyzed with SPSS version 18.0. Univariate (χ 2 test) and multivariate (multiple logistic regression) analyses assessing risk factors for PAP were performed to estimate the odds ratios (Ors) with 95% confidence intervals (cIs). The intra-and interobserver agreement were calculated by kappa statistics. A total of 134 subjects were enrolled, with 59 men and 75 women. Mean age was 66.0 ± 11.4 years (range, 35 to 91 years), with 36 patients (26.9%) younger than age 60 and 98 patients (73.1%) older than 60. Considering BMI, 8 patients (6.0%) were in the underweight group, 42 patients (31.3%) were in normal range, and 84 patients (62.7%) were in the overweight group. Eighty-four out of 134 (62.7%), 32 (23.9%), 4 (3.0%), and 14 (10.5%) patients had open-angle results glaucoma, angle-closure glaucoma, secondary glaucoma, and OHT, respectively. There were 70 (52.2%), 21 (15.7%), and 43 (32.1%) eyes that received components of 0.005% latanoprost, 0.004% travoprost, and 0.03% bimatoprost. Of these, 49 patients (36.6%) received concurrent 0.5% timolol (24 out of 49) or fixed combination (25 out of 49). Twenty-three patients (17.1%) were treated with PGAs for 3-6 months and the remaining (82.8%) for more than 6 months (Table 1) .
Factors associated With PaP
The prevalence of PAP in this study was 44.8% (95% CI, 36.3-53.3%). In univariate analysis, PAP was more common in 0.03% bimatoprost and 0.004% travoprost compared with 0.005% latanoprost. In multivariate analysis, the factors significantly associated with PAP were 0.03% bimatoprost (OR, 4.0; CI, 1.6-9.5) and 0.004% travoprost (OR, 3.3; CI, 1.1-10.1) when compared with latanoprost (the first PGA), age greater than 60 years (OR, 3.0; CI, 1.2-7.8), and timolol (OR, 2.9; CI, 1.3-6.8).
The group of patients who received PGAs with timolol, either concurrently or in fixed combination, developed PAP as follows: 11 out of 20 (55%) receiving latanoprost with timolol, 9 out of 13 (69.2%) receiving travoprost with timolol, whereas only 8 out of 16 (50%) in the group receiving bimatoprost with timolol. On the other hand, in 28 patients who developed PAP while using PGAs with timolol, 11 (39.3%) of them used latanoprost, 9 (32.1%) used travoprost, and 8 (28.6%) used bimatoprost. In the present study, being overweight was also found to be significantly associated with PAP but in the reverse fashion (OR, 0.02; CI, 0.1-0.7). No significant associations between PAP and sex, duration of PGA use, or type of glaucoma were shown (Table 2) . 
intra-and interobserver reliability
Intraobserver reliability for PAP diagnosis between the 2 glaucoma specialists was almost perfect (kappa = 0.82). Substantial agreement (kappa = 0.66) along with interobserver reliability revealed moderate agreement (kappa = 0.54) in the first assessment and substantial agreement (kappa = 0.63) in the second assessment (Table 3 ).
This study focused on the risk and protective factors discussion associated with PAP. Seven characteristics of PAP were employed to better evaluate patients than the single use of DUES, as indicated by most previous studies.
The mechanism of PAP was first described as effects to the Muller muscle by Peplinski et al. 5 Later, PGA-induced lipolysis upon stimulation of the prostaglandin F (FP) receptor in orbital tissue was believed to cause DUES. 13 Recently, most findings of PAP are thought to be caused by orbital fat atrophy from inhibition of adipogenesis through FP receptor stimulation.
14 The differences in pharmacokinetics among types of PGAs may affect periorbital change. We found that the prevalence of PAP in glaucoma and OHT patients at KCMH classified by types of PGAs (Table 2 ) was similar to the incidence of DUES in previous studies. Deepening of the upper eyelid sulcus was identified objectively in 6%, 53%, and 60% of patients treated with latanoprost, travoprost, and bimatoprost. 6, 8, 15 Compared with 0.005% latanoprost, our study found that 0.004% travoprost and 0.03% bimatoprost were more likely to induce PAP. Sakata et al 16 reported the recovery rate from bimatoprost-induced DUES after switching treatment to 0.005% latanoprost, where DUES was reduced or disappeared in 85% of patients.
A recent study found that orbital fat showed positive correlations with BMI. 17 Overweight or high BMI patients tend to have more orbital fat volume. According to a previously proposed mechanism of reduction of orbital adipose tissue, we studied the association between BMI and PAP. Being overweight or obese was probably a protective factor for PAP. This may be because more reserved orbital fat volume affected the rate of adipogenesis reduction, making it more difficult to detect the appearance of PAP.
The duration of PGA administration and sex were not associated with PAP in the present and previous studies. [7] [8] [9] 18, 19 Inoue et al 9 reported no significant difference in the frequency of DUES found in different drug administration periods. In our study, the results supported his findings that duration was not a significant risk factor for PAP.
Older age was found to be a risk factor for PAP in this study. Some studies have reported that the incidence of DUES significantly increased with age, 6,8 but others found no relation between DUES and age. 7, 9, 18, 19 Changes due to aging may be difficult to differentiate from PAP because aging can also lead to orbital fat loss. Rabinowitz et al 11 recommended that the only way to differentiate PAP from age-related change is to evaluate the change in monocular PGA users. Furthermore, they proposed that ptosis was a characteristic of aging, whereas PAP causes upper eyelid retraction, which is in contrast to other studies.
Topical timolol can cause dry eye, blurred vision, and reported systemic side effects such as bradycardia, shortness of breath, and fatigue. There were previous case reports of topical timolol causing blepharoptosis and diplopia in patients who were diagnosed with myasthenia gravis and ocular myasthenia gravis. 20, 21 However, no previous studies were found indicating that timolol leads to ptosis in nonmyasthenia gravis patients or periorbitopathy. Interestingly, our study showed that 0.5% timolol possibly precipitated periorbital change when used in addition to PGAs. The majority of the 49 patients receiving PGAs and 0.5% timolol in combination who developed PAP (28/49) were using latanoprost (11 out of 28, 39.3%), followed by travoprost (9 out of 28, 32.1%) and fewer in combination with bimatoprost (8 out of 28, 28.6%). It has been postulated that timolol may block β2-adrenoceptor agonistic effects; consequently, the unopposed α1-adrenoceptor agonistic effects of endogenous catecholamines or timolol and antagonism of β2-adrenoceptors could reduce nitric oxide production, a mediator of bimatoprost-associated hyperemia. Both theories were used to explain the mechanisms of reduced conjunctival hyperemia in eyes receiving fixed combination PGAs/timolol compared with those receiving PGAs alone. [22] [23] [24] Therefore, if this reduced vasodilating effect were related to the PAP precipitating effect of timolol when in combination, PGAs would be absorbed less from the ocular surface and take longer to penetrate and act on the orbital fat cells. However, the true mechanisms of 0.5% timolol in precipitating PAP are not clearly understood and further studies are needed.
Although some studies showed PAP recovery after existing PGA cessation or switching to another PGA, 10,16 they did not report the recovery rate after long-term exposure. In patients who receive bilateral PGAs, it may be more difficult to detect PAP. Pretreatment evaluation and observation of periorbital change during treatment are needed. All patients should be informed about this side effect when the drugs are prescribed.
There are some limitations to this study. Firstly, this study is cross-sectional; therefore, we could not observe the patients from the beginning of PGA use and the incidence of PAP could not be evaluated. Secondly, the photographs are limited in their ability to show stereopsis, so DUES and enophthalmos are difficult to evaluate. Another limitation is that PAP was diagnosed by clinical appearance, which is subjective and depends on examiners' experience.
In conclusion, our study confirmed older age, bimatoprost, and travoprost were more associated with PAP than latanoprost, whereas high BMI was found to be a protective factor. Furthermore, timolol possibly precipitated periorbital change when in use with prostaglandins. This may help in choosing the proper medications for individual patients.
